Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLE-aCD123
- Development stage
- Unknown
- Lead developer
- Innorna
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LLE-aCD123 is an investigational mRNA-based therapeutic developed by InnoRNA Biotech for the treatment of acute myeloid leukemia (AML). The drug utilizes InnoRNA's proprietary Lipid-Like Envelope (LLE) delivery system to encapsulate mRNA encoding a bispecific T-cell engager (BiTE). This BiTE is designed to simultaneously target CD123 (Interleukin-3 receptor alpha), which is highly expressed on AML blasts and leukemic stem cells, and CD3 on the surface of T-cells. Upon administration, the mRNA is translated in vivo, leading to the production of the bispecific antibody which facilitates the formation of an immunological synapse between cytotoxic T-cells and malignant cells, resulting in targeted cell lysis. This approach aims to combine the potent efficacy of bispecific antibodies with the transient expression and potentially improved safety profile afforded by mRNA-based delivery.
- Other names
- mRNA-encoded anti-CD123 x CD3 bispecific antibodyInnoRNA CD123 mBITE
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on LLE-aCD123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLE-aCD123.